OVID - Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference | Benzinga
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York.
A live webcast of the Cantor Fitzgerald presentation can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 90 days.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and intractable brain disorders with courageous science. The Company is advancing a focused pipeline of targeted small molecule candidates to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitation, which can cause seizures and other neuropathological symptoms. Programs Ovid seeks to develop include: GV101, a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations; OV329, a GABA-aminotransferase inhibitor, for the potential treatment of treatment-resistant seizures; and OV350, ...